18F-FLT PET/CT 早期评估急性髓系白血病诱导治疗反应
本研究纳入10例经组织学确诊并接受诱导治疗的成人急性髓系白血病患者,诱导完成后行18F-FLT PET/CT,视觉与定量评估骨髓摄取,超过三分之一长骨及全中枢骨骼骨髓摄取强烈增高判为耐药病PET阳性。PET阳性与阴性组标准摄取值差异显著,5例CR/CRi患者PET阴性但3例CR患者PET阳性,2例耐药病均为PET阳性。结论认为18F-FLT PET/CT对评估耐药病有良好敏感性和阴性预测值,可能有助于早期评估治疗反应并提供预后价值。
要点
- 10例成人AML患者诱导后行18F-FLT PET/CT,5例判为PET阳性、5例PET阴性。
- PET阳性与阴性组标准摄取值差异显著,2例耐药病均为PET阳性。
- 5例CR/CRi患者PET阴性,但3例CR患者PET阳性,其中2例PET阳性CR患者巩固后4个月复发或高度怀疑复发。
核心结论
- 诱导治疗后18F-FLT PET/CT对评估AML耐药病显示出良好敏感性和阴性预测值。
- 这项初步研究提示18F-FLT PET/CT可能作为无创工具用于早期评估治疗反应,并可能为AML患者生存提供预后价值。
研究设计与样本
- 纳入经组织学确诊并接受诱导治疗的成人AML患者,诱导完成后行18F-FLT PET/CT,图像进行视觉与定量评估。
- 超过三分之一长骨及全中枢骨骼骨髓摄取强烈增高者判为耐药病PET阳性,PET结果与临床反应及结局比较。
主要发现
- 10例可评估患者(7男3女,中位年龄58岁)中,5例判为PET阳性、5例PET阴性。
- PET阳性组与PET阴性组标准摄取值差异显著。
- 10例中8例达到临床完全缓解(CR)/血细胞计数未完全恢复的CR(CRi);5例CR/CRi患者PET阴性,但3例CR患者PET阳性。
- 2例耐药病患者均为PET阳性。
- 随访期间,2例PET阳性的CR患者在巩固治疗后4个月复发或高度怀疑复发。
临床怎么用
- 作者认为18F-FLT PET/CT可能作为无创工具用于早期评估AML治疗反应,并可能提供预后价值。
局限性
- 原文称本研究为初步研究(preliminary study),并认为18F-FLT PET/CT可能作为无创工具、可能提供预后价值,结论采用可能语气。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We evaluated the suitability of 18F-fluorodeoxythymidine (18F-FLT) positron emission tomography (PET)/computed tomography (CT) for assessment of the early response to induction therapy and its value for predicting clinical outcome in patients with acute myeloid leukemia (AML). Adult patients who had histologically confirmed AML and received induction therapy were enrolled. All patients underwent 18F-FLT PET/CT after completion of induction. PET/CT images were visually and quantitatively assessed. Cases with intensely increased bone marrow uptake in more than one third of the long bones and throughout the central skeleton were interpreted as PET-positive for resistant disease (RD). PET results were compared to the clinical response and outcome. RESULTS: In visual PET analysis of 10 eligible patients (7 male, 3 female; median age 58 years), 5 patients were interpreted as being PET-positive and 5 as PET-negative. Standardized uptake values were significantly different between PET-positive and PET-negative groups. Eight of 10 patients achieved clinical complete remission (CR)/CR with incomplete blood count recovery (CRi). Five CR/CRi patients had PET-negative findings, but 3 CR patients had PET-positive findings. Both of the RD patients had PET-positive findings. During follow-up, 2 CR patients with PET-positive findings relapsed, or were strongly suspected of relapse, 4 months after consolidation. CONCLUSION: 18F-FLT PET/CT after induction therapy showed good sensitivity and negative-predictive value for evaluating RD in patients with AML. This preliminary study suggests that 18F-FLT PET/CT may be valuable as a noninvasive tool for early assessment of the response to treatment and may provide prognostic value for survival in patients with AML.
引用
- Han EJ, Lee BH, Kim JA, et al. Early assessment of response to induction therapy in acute myeloid leukemia using 18F-FLT PET/CT. EJNMMI Res. 2017. PMID: 28916904. doi:10.1186/s13550-017-0326-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。